XtalPi scores landmark deal for AI drug discovery
The biotech has partnered with U.S. firm DoveTree in a collaboration worth up to $5.99 billion, adding to a slew of major deals for Chinese research firms this year Key…
Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
FAST NEWS: 3SBio Sees Profit Doubling on Surging Revenues
The latest: 3SBio Inc. (1530.HK) released a positive profit forecast on Monday evening, estimating its net profit rose 100% to 120% for 2021, while its profit attributable to equity shareholders…
Recent Articles
RELATED ARTICLES
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
BRIEF: XtalPi acquires British chiral molecule developer
2228.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
